Top
News Updates

Fresh Writ Petition filed against Ranbaxy Laboratories

Live Law News Network
5 Aug 2013 3:00 PM GMT
Fresh Writ Petition filed against Ranbaxy Laboratories
x
Your free access to Live Law has expired
To read the article, get a premium account.
    Your Subscription Supports Independent Journalism
Subscription starts from
599+GST
(For 6 Months)
Premium account gives you:
  • Unlimited access to Live Law Archives, Weekly/Monthly Digest, Exclusive Notifications, Comments.
  • Reading experience of Ad Free Version, Petition Copies, Judgement/Order Copies.
Already a subscriber?
Advocate Manohar Lal Sharma has today filed a fresh petition against pharma company Ranbaxy Laboratories for allegedly manufacturing and supplying 30 drugs under insanitary conditions with inferior materials in India.

Central Drug Standard Control Organization and the Central Bureau of Investigation have been made respondents in the present petition.

The present petition seeks to:

1. To direct the Central Bureau of Investigation to initiate investigation and to prosecute all ex and present directors of the Ranbaxy under sections 326, 327, 320, 420 & 120-B of IPC read with sections 27A & 18 of the Drugs and Cosmetics Act of 1940.

2. To direct to the Union of India to cancel all drug manufacturing licenses issued to the Ranbaxy & their group companies.

3. To prohibit Ranbaxy from supplying any medicines in India.

4. To direct the Central Bureau of Investigation to initiate investigation against the officials of Central Drug Standards Control Organization for allegedly helping Ranbaxy.

As reported by Live Law earlier, another petition [WP (Criminal) 98 of 2013] filed by Sharma alleging that Ranbaxy was manufacturing and selling substandard drugs in India was dismissed by the Supreme Court due to lack of sufficient evidence against the company. However the Supreme Court gave the liberty to Sharma to file a fresh petition if details of the medicines were secured.
Next Story